JP2020143156A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020143156A5 JP2020143156A5 JP2020097344A JP2020097344A JP2020143156A5 JP 2020143156 A5 JP2020143156 A5 JP 2020143156A5 JP 2020097344 A JP2020097344 A JP 2020097344A JP 2020097344 A JP2020097344 A JP 2020097344A JP 2020143156 A5 JP2020143156 A5 JP 2020143156A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- patient
- dose
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 208000029078 coronary artery disease Diseases 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 9
- 102000036639 antigens Human genes 0.000 claims 9
- 108091007433 antigens Proteins 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 9
- 108010028554 LDL Cholesterol Proteins 0.000 claims 5
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 206010002388 Angina unstable Diseases 0.000 claims 2
- 208000032382 Ischaemic stroke Diseases 0.000 claims 2
- 101710180553 Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 claims 2
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 claims 2
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 2
- 208000007814 Unstable Angina Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 2
- 231100000682 maximum tolerated dose Toxicity 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 230000000250 revascularization Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 101710095342 Apolipoprotein B Proteins 0.000 claims 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- 201000000057 Coronary Stenosis Diseases 0.000 claims 1
- 206010011089 Coronary artery stenosis Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 208000033463 Ischaemic neuropathy Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 230000005856 abnormality Effects 0.000 claims 1
- 238000002583 angiography Methods 0.000 claims 1
- 230000000923 atherogenic effect Effects 0.000 claims 1
- 230000007214 atherothrombosis Effects 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000000090 biomarker Substances 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 210000004351 coronary vessel Anatomy 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000002045 lasting effect Effects 0.000 claims 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002107 myocardial effect Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
- 229960000672 rosuvastatin Drugs 0.000 claims 1
- BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims 1
- 238000010254 subcutaneous injection Methods 0.000 claims 1
- 239000007929 subcutaneous injection Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022116854A JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
| JP2024115429A JP2024147744A (ja) | 2014-03-17 | 2024-07-19 | 心血管リスクを低減させる方法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954094P | 2014-03-17 | 2014-03-17 | |
| US61/954,094 | 2014-03-17 | ||
| US201462025400P | 2014-07-16 | 2014-07-16 | |
| US62/025,400 | 2014-07-16 | ||
| US201462043182P | 2014-08-28 | 2014-08-28 | |
| US62/043,182 | 2014-08-28 | ||
| EP15305293.1 | 2015-02-26 | ||
| EP15305293 | 2015-02-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556709A Division JP2017509624A (ja) | 2014-03-17 | 2015-03-13 | 心血管リスクを低減させる方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022116854A Division JP2022141868A (ja) | 2014-03-17 | 2022-07-22 | 心血管リスクを低減させる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020143156A JP2020143156A (ja) | 2020-09-10 |
| JP2020143156A5 true JP2020143156A5 (enExample) | 2021-05-20 |
Family
ID=66624745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020097344A Pending JP2020143156A (ja) | 2014-03-17 | 2020-06-04 | 心血管リスクを低減させる方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2020143156A (enExample) |
| IL (1) | IL247837A0 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102517894B1 (ko) * | 2021-02-23 | 2023-04-04 | 연세대학교 산학협력단 | 당뇨발에 의한 하지 절단 수술의 치료 반응성을 예측하는 방법 |
-
2016
- 2016-09-15 IL IL247837A patent/IL247837A0/en unknown
-
2020
- 2020-06-04 JP JP2020097344A patent/JP2020143156A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017509624A5 (enExample) | ||
| von Haehling et al. | Improving exercise capacity and quality of life using non-invasive heart failure treatments: evidence from clinical trials | |
| JP2017506626A5 (enExample) | ||
| JPWO2019173530A5 (enExample) | ||
| EP1696900B1 (en) | Use of treprostinil to treat ischemic lesions | |
| JP2017528427A5 (enExample) | ||
| JP2025011161A5 (enExample) | ||
| JP2017160208A5 (enExample) | ||
| JP2014516953A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| JP2017522316A5 (enExample) | ||
| JP2016538248A5 (enExample) | ||
| Olsson et al. | Safety and tolerability of an immediate-release formulation of the oral direct thrombin inhibitor AZD0837 in the prevention of stroke and systemic embolism in patients with atrial fibrillation | |
| CN107922507A (zh) | 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者 | |
| US20230225997A1 (en) | Methods of administering sotalol hydrochloride | |
| JP2020143156A5 (enExample) | ||
| JP5837877B2 (ja) | 静脈内投与イブプロフェンを用いた患者の治療 | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| JP2008540456A (ja) | 血管疾患の治療 | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| US20110033474A1 (en) | Inhibition of platelet aggregation | |
| JP2020535139A (ja) | シポニモドの投与レジメン | |
| AU2001225625B2 (en) | Use of melagatran for manufacture of a medicament for the treatment of ischemic disorders | |
| Lopera et al. | Drugs as possible triggers of takotsubo cardiomyopathy-update 2022: Systematic review | |
| TW201929894A (zh) | 對抗心臟疾病、心血管疾病及相關病況與症狀之治療及保護方法 |